Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aristi P Fernandes

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
Biochimica Et Biophysica Acta|December 3, 2014
Selenium compounds as therapeutic agents in cancerAristi P Fernandes, Valentina Gandin
Molecules (Basel, Switzerland)|July 18, 2015
Metal- and Semimetal-Containing Inhibitors of Thioredoxin Reductase as Anticancer AgentsValentina Gandin, Aristi P Fernandes
The EPMA Journal|December 4, 2012
Selenium in the prevention of human cancersMikael Björnstedt, Aristi P Fernandes
Free Radical Biology & Medicine|May 11, 2018
Organic selenium compounds as potential chemotherapeutic agents for improved cancer treatmentValentina Gandin, Prajakta Khalkar, Jeremy Braude, et al.
Journal of the American Chemical Society|November 11, 2017
Heterogeneous Rupturing DendrimersOliver C J Andrén, Aristi P Fernandes, Michael Malkoch
Free Radical Biology & Medicine|May 28, 2014
Protective effects of the thioredoxin and glutaredoxin systems in dopamine-induced cell deathLisa Arodin, Antonio Miranda-Vizuete, Peter Swoboda, et al.
The FEBS Journal|November 8, 2015
Bacterial thioredoxin and thioredoxin reductase as mediators for epigallocatechin 3-gallate-induced antimicrobial actionWei Liang, Aristi P Fernandes, Arne Holmgren, et al.
The Biochemical Journal|April 23, 2010
Selenium compounds are substrates for glutaredoxins: a novel pathway for selenium metabolism and a potential mechanism for selenium-mediated cytotoxicityMarita Wallenberg, Eric Olm, Christina Hebert, et al.
Antioxidants & Redox Signaling|September 23, 2009
Selenium and the selenoprotein thioredoxin reductase in the prevention, treatment and diagnostics of cancerMarkus Selenius, Anna-Klara Rundlöf, Eric Olm, et al.
Molecular Oncology|August 12, 2016
A ribonucleotide reductase inhibitor with deoxyribonucleoside-reversible cytotoxicityMikael Crona, Paula Codó, Venkateswara Rao Jonna, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
Biochimica Et Biophysica Acta|December 3, 2014
Selenium compounds as therapeutic agents in cancerAristi P Fernandes, Valentina Gandin
Molecules (Basel, Switzerland)|July 18, 2015
Metal- and Semimetal-Containing Inhibitors of Thioredoxin Reductase as Anticancer AgentsValentina Gandin, Aristi P Fernandes
The EPMA Journal|December 4, 2012
Selenium in the prevention of human cancersMikael Björnstedt, Aristi P Fernandes
Free Radical Biology & Medicine|May 11, 2018
Organic selenium compounds as potential chemotherapeutic agents for improved cancer treatmentValentina Gandin, Prajakta Khalkar, Jeremy Braude, et al.
Journal of the American Chemical Society|November 11, 2017
Heterogeneous Rupturing DendrimersOliver C J Andrén, Aristi P Fernandes, Michael Malkoch
Free Radical Biology & Medicine|May 28, 2014
Protective effects of the thioredoxin and glutaredoxin systems in dopamine-induced cell deathLisa Arodin, Antonio Miranda-Vizuete, Peter Swoboda, et al.
The FEBS Journal|November 8, 2015
Bacterial thioredoxin and thioredoxin reductase as mediators for epigallocatechin 3-gallate-induced antimicrobial actionWei Liang, Aristi P Fernandes, Arne Holmgren, et al.
The Biochemical Journal|April 23, 2010
Selenium compounds are substrates for glutaredoxins: a novel pathway for selenium metabolism and a potential mechanism for selenium-mediated cytotoxicityMarita Wallenberg, Eric Olm, Christina Hebert, et al.
Antioxidants & Redox Signaling|September 23, 2009
Selenium and the selenoprotein thioredoxin reductase in the prevention, treatment and diagnostics of cancerMarkus Selenius, Anna-Klara Rundlöf, Eric Olm, et al.
Molecular Oncology|August 12, 2016
A ribonucleotide reductase inhibitor with deoxyribonucleoside-reversible cytotoxicityMikael Crona, Paula Codó, Venkateswara Rao Jonna, et al.
Pageof 3